

S 642

Finn Sawyer Access to Cancer Testing Act

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 2, 2023

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 2, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/642>

Sponsor

Name: Sen. Klobuchar, Amy [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Wicker, Roger F. [R-MS]	R · MS		Mar 2, 2023

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 2, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 1780	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.

Summary (as of Mar 2, 2023)

Finn Sawyer Access to Cancer Testing Act

This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer.

Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

Actions Timeline

- **Mar 2, 2023:** Introduced in Senate
- **Mar 2, 2023:** Read twice and referred to the Committee on Finance.